Germany - Drugs

Description

The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130c (1) SGB V in conjunction with Section 130a (8) SGB V on drugs with the active ingredient teriflunomide (ATC: L04AA31) within the framework of a so-called "open-house model". § Section 130a (8) SGB V for drugs with the active ingredient teriflunomide (ATC: L04AA31) within the framework of a so-called "open-house model". Under the stipulation of uniform contract conditions as well as a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of or access to a rebate contract pursuant to Section 130c (1) SGB V in conjunction with Section 130a (8) SGB V for the active ingredients listed in Section B. Interested pharmaceutical companies can apply for this. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address mentioned under I.1). A prerequisite for the conclusion of an agreement is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed.
Conclusion of non-exclusive discount agreements according to § 130c para. 1 SGB V in conjunction with § 130a para. 8 SGB V § Section 130a (8) SGB V for drugs with the active ingredient teriflunomide (ATC: L04AA31) with the possibility of concluding agreements at any time within the framework of a so-called "open-house model". A contract is concluded with each pharmaceutical company that fulfils the conditions for participation. There is no exclusivity, and joining or concluding a contract can be done at any time and under the same conditions. Individual contract negotiations are not carried out. The earliest start of the contract is 1.4.2021. Based on this, the contract period is a maximum of 12 months. The contract ends on 31.3.2022 regardless of the start date. Should the AOK Saxony-Anhalt invite tenders for exclusive contracts for the active substances during the term of the contract in accordance with the relevant provisions of public procurement law, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual provisions.This publication does not constitute the award of a public contract within the meaning of Section 103 GWB or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, the publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice is used. The resulting conceptual specifications, such as the procedural designation "open procedure", are solely due to the use of this publication form and the publication platform. A further meaning, in particular a submission to procurement law regulations, as far as they are not obligatory for legal reasons, is not connected with it.

Opportunity closing date

28 January 2022

Value of contract

to be confirmed